Buprenorphine/Raltegravir Pharmacokinetic Interaction Study
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this protocol is to study the effect of an HIV medication known as
Raltegravir on Buprenorphine in people who have been receiving the same dose of Buprenorphine
for at least 3 weeks before study entry. This will be determined by giving Raltegravir along
with Buprenorphine and by measuring the amount of Raltegravir and Buprenorphine in the blood.
The investigators will also learn about the effects of Buprenorphine on Raltegravir and about
the safety of taking these two medications together.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborators:
Merck Sharp & Dohme Corp. National Institute on Drug Abuse (NIDA)